Original Article – Case Study

Anaplastic testicular seminoma presenting as a hydrocele, in a 36-year-old patient with a family history of anaplastic seminoma

Orestis Ioannidis¹, Anastasia Malliora¹, Panagiotis Christidis¹*, Lydia Loutzidou¹, Elissavet Anestiadou¹, Savvas Symeonidis¹, Nikolaos Ouzoundis¹, Vassilis Foutsitzis¹, Ioannis Mantzoros¹, Stamatis Angelopoulos¹

¹ 4th Academic Department of General Surgery, Aristotele University of Thessaloniki, General Hospital of Thessaloniki “G. Papanikolaou”, Thessaloniki, Greece

*Corresponding authors: Panagiotis Christidis MD, MSc, General Hospital of Thessaloniki “G. Papanikolaou”, Leoforos Papanikolaou 90, Exoichi, PC 57010, Thessaloniki, Greece; Phone: 0030 2313307029; Email: panagiotischristidis13@gmail.com.

Submitted: February 13, 2022; Revised: June 27, 2022; Accepted: June 27, 2022; Published: June 30, 2022

Citation: Ioannidis O, Malliora A, Christidis P, Loutzidou L, Anestiadou E, Symeonidis S et al. Anaplastic testicular seminoma presenting as a hydrocele, in a 36-year-old patient with a family history of anaplastic seminoma. Discoveries 2022; 10(2): e149. DOI: 10.15190/d.2022.8

ABSTRACT

Testicular cancer is the solid tumor with the greatest incidence in men between 15 and 44 years old. Its main histological type is germ cell tumor, that is divided into seminomatous and non-seminomatous tumors. Seminoma, consisting 55% of testicular cancer, manifests in the fourth decade of men’s life and a rare type of it is the anaplastic seminoma (5% to 15% of testicular seminoma). Diagnosis is based on clinical examination, testicular ultrasound, magnetic resonance imaging, tumor markers measurement and pathological examination, while treatment of choice is radical orchiectomy, with or without retroperitoneal lymphadenectomy, potentially followed by radiotherapy or chemotherapy.

We present the case of a 36-year-old male patient, whose father suffered from anaplastic seminoma and visited the hospital due to a painless hydrocele. The testicle was swollen and hard on palpation, while cytological examination of the drained fluid detected neoplasm, potentially seminoma. Tumor markers measurement, as well as abdominal and pelvic computerized tomography scans, were evaluated and the patient was staged as IIA, according to the American Joint Commission on Cancer. Radical orchiectomy with high ligation of the seminal vesicle was performed and the pathological examination showed anaplastic testicular seminoma. Postoperatively, four cycles of chemotherapy with bleomycin, etoposide and platinum (BEP) were performed and no signs of recurrence were present after 1 year. In conclusion, anaplastic seminoma has a good prognosis and is suggested to be treated with radical orchiectomy, with or without retroperitoneal lymphadenectomy, potentially followed by radiotherapy or chemotherapy.

Keywords

Testicular cancer, seminoma, anaplastic cancer, hydrocele, family history of seminoma.

INTRODUCTION

In Western countries, testicular cancer accounts for 1% of male malignancies and 5% of urological cancers. Its main histological type is germ cell tumor (GCT), that is divided into seminomatous and non-seminomatous tumors. Seminoma, consisting of 55% of testicular cancer is most commonly manifested in the fourth decade of men’s life as a
palpable mass and a rare type of it, documented by a few publications in the literature, is anaplastic seminoma (5% to 15% of testicular seminoma). We present the case of a 36-year-old male patient with a family history of anaplastic seminoma who suffered from anaplastic seminoma and was successfully treated with radical orchiectomy followed by chemotherapy. Written informed consent was obtained from the patient, and the institutional review board of our hospital approved this report. The following case report is presented in accordance with Surgical CAse REport (SCARE) guidelines.

**CASE REPORT**

A 36-year-old patient, with a family history of anaplastic seminoma from his father, came to the hospital with a painless hydrocele that presented at least two months before. Palpation revealed swelling and hardness of the testicle. Drainage was performed. The cytological examination of the fluid detected a neoplasm and a seminoma was suspected.

During the preoperative examination, blood and imaging tests were performed. Alpha-fetoprotein (AFP) (normal values: 0 and 8 ng/mL) and lactate dehydrogenase (LDH) values (normal values: 140 to 280 U/L) were within normal limits, whereas beta-human chorionic gonadotropin (β-hCG) was elevated 600IU/L (normal values: 0.02-0.8IU/L). Chest radiography was normal, whereas pelvic and abdominal computerized tomography (CT) scans showed a small number of swollen inguinal and paraaortic lymph nodes below the level of the renal arteries and the patient was staged as II according to the American Joint Commission on Cancer (AJCC).

No prior biopsy of the testicular mass was performed due to the risk of tumor seeding via lymphatic drainage. The patient underwent radical orchiectomy in classic fashion with high ligation of the seminal vesicle (Figure 1). Pathological examination of the mass showed nuclear pleomorphism, high mitotic rates and focal areas of necrosis. Thus, it was categorized as an anaplastic testicular seminoma.

The patient was discharged in the 2nd postoperative day. He underwent four cycles of chemotherapy with bleomycin, etoposide and platinum (BEP). The laboratory and imaging re-examination at 3, 6, 9 and 12 months were within the normal limits, with no sign of recurrence.

**DISCUSSION**

In Western countries, although testicular cancer only accounts for 1% of male malignancies and 5% of urological cancers, it is the solid tumor with the greatest incidence in men between 15 and 44 years old. Its main histological type (95%) is germ cell tumor (GCT) that is divided into seminomatous and non-seminomatous tumors. A rare type of seminoma, with a few publications in the literature, is anaplastic seminoma (5% to 15% of testicular seminoma), which is separated from classical seminoma based on the greater mitotic activity, the cellular irregularity, the absence of fibrovascular septae, the presence of a few lymphocytes, the focal...
Anaplastic testicular seminoma presenting as hydrocele

Anaplastic seminoma is thought to have a prognosis comparable to the classical seminoma, with a 5-year survival rate that ranges from 43% to 95%\(^5\) or according to others up to 80%\(^9\). Treatment of choice for testicular GCT, including seminoma, is radical orchidectomy, with or without retroperitoneal lymphadenectomy, that could be followed by radiotherapy or chemotherapy\(^7\), depending on stage, histology and risk classification\(^3\). Radiotherapy is performed in stage IIA seminoma of small size and in selective cases of stage IIB, while chemotherapy is chosen for IIB, IIC and III stages and it includes etoposide and cisplatin (EP) or bleomycin, etoposide, and cisplatin (BEP)\(^2\). Four cycles of chemotherapy with BEP were chosen to be performed on our patient. Anaplastic seminoma treatment is believed to be the same as the one performed for seminoma\(^1\). Today, new treatments, such as immunotherapy, are being considered\(^7\).

CONCLUSION

In conclusion, seminoma is the most common type of testicular cancer that can be rarely manifested as anaplastic. Despite the limited information about this histological type, anaplastic seminoma is considered to have good prognosis. Family history is a risk factor. Anaplastic seminoma is suggested to be treated as the classic seminoma with radical orchidectomy, with or without retroperitoneal lymphadenectomy, potentially followed by radiotherapy or chemotherapy.

Conflict of Interest

The authors declare no competing interests.

Acknowledgements

The authors declare that they have none to acknowledge.

REFERENCES

1. Crema M, Mirone V, Di Meo S, Buonopane R, Longo N, Fusco F, Forte NR, Imperatore V. A case of highly aggressive anaplastic seminoma of the testis presenting as fungating scrotal lesion. Arch Ital Urol Androl. 2017 Jun 30;89(2):158-159.
2. Marko J, Wolfman DJ, Aubin AL, Sesterhenn IA. Testicular Seminoma and Its Mimics: From the Radiologic Pathology Archives. Radiographics. 2017;37(4):1085-1098.
3. Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH et al. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 Dec;17(12):1529-1554

4. Agha RA, Fowler AJ, Saeta A, et al. The SCARE Statement: Consensus-based surgical case report guidelines. Int J Surg. 2016;34:180-186. doi:10.1016/j.ijsu.2016.08.014

5. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-99. doi:10.3322/caac.21388.

6. Fukawa T, Kanayama HO. Current knowledge of risk factors for testicular germ cell tumors. Int J Urol. 2018 Apr;25(4):337-344.

7. Batool A, Karimi N, Wu XN, Chen SR, Liu YX. Testicular germ cell tumor: a comprehensive review. Cell Mol Life Sci. 2019 May;76(9):1713-1727.

8. Bobba VS, Mittal BB, Hoover SV, Kepka A. Classical and anaplastic seminoma: difference in survival. Radiology. 1988 Jun;167(3):849-52.

9. Sarid DL, Ron IG, Avinoach I, Sperber F, Inbar MJ. Spontaneous regression of retroperitoneal metastases from a primary pure anaplastic seminoma: a case report. Am J Clin Oncol. 2002 Aug;25(4):380-2.

This article is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and it is not used for commercial purposes; 2022, Ioannidis O et al., Applied Systems and Discoveries Journals.